Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-11-24

FDA Approved: ELETRIPTAN HYDROBROMIDE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

The FDA approved a supplemental application for Eletriptan hydrobromide from Aurobindo Pharma Limited, authorizing its continued use as a generic treatment for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Eletriptan Hydrobromide (eletriptan hydrobromide)

Snippet

SUPPL AP for ELETRIPTAN HYDROBROMIDE (ELETRIPTAN HYDROBROMIDE)